BRPI0416118A - phosphodiesterase 9 inhibition as a treatment for obesity-related conditions - Google Patents
phosphodiesterase 9 inhibition as a treatment for obesity-related conditionsInfo
- Publication number
- BRPI0416118A BRPI0416118A BRPI0416118-1A BRPI0416118A BRPI0416118A BR PI0416118 A BRPI0416118 A BR PI0416118A BR PI0416118 A BRPI0416118 A BR PI0416118A BR PI0416118 A BRPI0416118 A BR PI0416118A
- Authority
- BR
- Brazil
- Prior art keywords
- pde9
- phosphodiesterase
- obesity
- inhibition
- treatment
- Prior art date
Links
- 101001117256 Drosophila melanogaster High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A Proteins 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 3
- 101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 206010033307 Overweight Diseases 0.000 abstract 1
- 229940076380 PDE9 inhibitor Drugs 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- RVEJWGYZBXCGGM-DNVCBOLYSA-N chembl2179094 Chemical compound C([C@H]([C@@H](C1)C=2NC(=O)C=3C=NN(C=3N=2)C2CCOCC2)C)N1CC1=CC=CC=C1 RVEJWGYZBXCGGM-DNVCBOLYSA-N 0.000 abstract 1
- 235000013330 chicken meat Nutrition 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 235000013372 meat Nutrition 0.000 abstract 1
- 235000020830 overeating Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Environmental Sciences (AREA)
- Physics & Mathematics (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Psychiatry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
Abstract
"INIBIçãO DA FOSFODIESTERASE 9 COMO TRATAMENTO PARA ESTADOS RELACIONADOS COM A OBESIDADE". A presente invenção dirige-se a métodos para diminuir o peso corporal e/ou a gordura corporal num animal, e.g., no tratamento de doentes com excesso de peso ou obesidade (e.g., humanos ou animais de companhia), ou como um meio para produzir carne mais magra em animais para alimentação (e.g., vacas, galinhas, porcos), e a métodos para tratar distúrbios alimentares (e.g., distúrbio de excesso de comida e bulimia) em doentes que deles necessitem através da administração de um inibidore de PDE9. A invenção também apresenta ferramentas iológicas para estudar em maior detalhe a função da PDE9, i.e., murganhos e células animais geneticamente modificados, possuindo um gene PDE9 desativado."INHIBITION OF PHOSPHODIESTERASE 9 AS A TREATMENT FOR OBESITY-RELATED STATES". The present invention is directed to methods for reducing body weight and / or body fat in an animal, eg, in treating overweight or obese patients (eg, humans or companion animals), or as a means to produce leaner meat in feed animals (eg, cows, chickens, pigs), and methods for treating eating disorders (eg, overeating disorder and bulimia) in patients in need thereof by administering a PDE9 inhibitor. The invention also features iological tools for studying in more detail the function of PDE9, i.e., genetically modified mice and animal cells, having a deactivated PDE9 gene.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51621303P | 2003-10-31 | 2003-10-31 | |
PCT/IB2004/003396 WO2005041972A1 (en) | 2003-10-31 | 2004-10-18 | Phosphodiesterase 9 inhibition as treatment for obesity-related conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0416118A true BRPI0416118A (en) | 2007-01-02 |
Family
ID=34549505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0416118-1A BRPI0416118A (en) | 2003-10-31 | 2004-10-18 | phosphodiesterase 9 inhibition as a treatment for obesity-related conditions |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1686998A1 (en) |
JP (1) | JP2007509923A (en) |
BR (1) | BRPI0416118A (en) |
CA (1) | CA2543522A1 (en) |
TW (1) | TW200526783A (en) |
WO (1) | WO2005041972A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015531401A (en) | 2011-10-10 | 2015-11-02 | ハー・ルンドベック・アクチエゼルスカベット | PDE9I having imidazopyrazinone skeleton |
CN107082783B (en) | 2012-01-26 | 2019-03-22 | H.隆德贝克有限公司 | PDE9 inhibitor with imidazotriazinones skeleton |
PL3865484T3 (en) | 2015-07-07 | 2024-04-22 | H. Lundbeck A/S | Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases |
EP4219709A1 (en) * | 2016-11-03 | 2023-08-02 | Temple University - Of The Commonwealth System of Higher Education | Dna plasmids for the fast generation of homologous recombination vectors for cell line development |
KR20210014662A (en) | 2018-05-25 | 2021-02-09 | 이마라 인크. | 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1, 5-a]Pyrazin-8-one monohydrate and crystalline form |
US20210386743A1 (en) * | 2018-10-08 | 2021-12-16 | The Johns Hopkins University | Use of pde9 inhibitors for treatment |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922595A (en) * | 1997-12-09 | 1999-07-13 | Incyte Pharmaceuticals, Inc. | Cyclic GMP phosphodiesterase |
WO2000047206A1 (en) * | 1999-02-12 | 2000-08-17 | Novo Nordisk A/S | Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation |
US20020165237A1 (en) * | 2000-08-11 | 2002-11-07 | Fryburg David Albert | Treatment of the insulin resistance syndrome |
US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
KR20040053210A (en) * | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
US20030181461A1 (en) * | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
-
2004
- 2004-10-18 WO PCT/IB2004/003396 patent/WO2005041972A1/en not_active Application Discontinuation
- 2004-10-18 JP JP2006537457A patent/JP2007509923A/en not_active Withdrawn
- 2004-10-18 EP EP04769658A patent/EP1686998A1/en not_active Withdrawn
- 2004-10-18 CA CA002543522A patent/CA2543522A1/en not_active Abandoned
- 2004-10-18 BR BRPI0416118-1A patent/BRPI0416118A/en not_active IP Right Cessation
- 2004-10-29 TW TW093133068A patent/TW200526783A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2005041972A1 (en) | 2005-05-12 |
CA2543522A1 (en) | 2005-05-12 |
TW200526783A (en) | 2005-08-16 |
JP2007509923A (en) | 2007-04-19 |
EP1686998A1 (en) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yap et al. | Repeated brief social defeat episodes in mice: effects on cell proliferation in the dentate gyrus | |
BRPI0413079A (en) | tasty ductile chewable veterinary composition | |
BRPI0606707A2 (en) | disubstituted urea as kinase inhibitors | |
TW200609219A (en) | Aryl-substituted piperazine derivatives | |
BR112012015961A2 (en) | compositions including pyruvate for pets and methods of use thereof | |
TW200510373A (en) | Substituted quinolin-4-ylamine analogues | |
BRPI0513953A (en) | methods for treating ccr2 mediated diseases or disorders | |
BRPI0416118A (en) | phosphodiesterase 9 inhibition as a treatment for obesity-related conditions | |
Dhungana et al. | Effect of music on animal behavior: a review | |
Greenberg et al. | Biological rhythms | |
Kostka et al. | Olfactory‐driven beta band entrainment of limbic circuitry during neonatal development | |
Ibebunjo et al. | Disparate dysfunction of skeletal muscles located near and distant from burn site in the rat | |
Sumanu et al. | Adverse effects of heat stress during summer on broiler chickens production and antioxidant mitigating effects | |
Morton | Adverse effects in animals and their relevance to refining scientific procedures | |
Janczarek et al. | Emotional response of young race horses to a transfer from a familiar to an unfamiliar environment. | |
Herskin et al. | Measuring cutaneous thermal nociception in group-housed pigs using laser technique—effects of laser power output | |
McCrackin et al. | Biology, handling, husbandry and anatomy | |
DE60324784D1 (en) | TREATMENT TO REDUCE INCREASE IN BODY WEIGHT | |
Lopez-Jimenez et al. | Effects of perinatal undernutrition and massage stimulation upon the ambiguus nucleus in the rat prior to weaning | |
BR112018005162B1 (en) | Use of lubabegron to reduce bovine emissions | |
Reiter et al. | Effect of reduced weight load on locomotor activity and leg disorders in broiler chickens | |
Kholikov et al. | Influence of estradiol diropionate (EDP) on the body growing birds | |
Beaver | Aggressive behavior problems | |
Fidan et al. | Effects of noise and light intensities on stress and fear reactions in broilers | |
CN216603169U (en) | Fixing device is used in animal doctor's treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: C12N 15/113 (2010.01), A01K 67/027 (2006.01), A61K |